Ruby Sharma, MD
Hematology & Oncology · New Hyde Park, NYNPI 1750589701
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.3% of the total across 3 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Daiichi Sankyo Inc. accounts for 94.3% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for hematology & oncology clinicians in NY, where the typical reported total is $1,337.
Across 3 payments — averaging $69.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$198
- Gilead$12
Across 226 payments — averaging $3173.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$279K
- Roche Products Limited$141K
- Eli Lilly$130K
- Hoffmann-la Roche Limited$81K
- Pfizer$79K
- AstraZeneca$6K
What the payments were for
- Food & beverage$19894%
- Education$126%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 2 | $198 |
| Gilead | 1 | $12 |
How this compares
$210 in reported general payments places this provider in the 20th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 64 | $993,652 |
| VerzenioAbemaciclib | 41 | $504,128 |
| KisqaliRibociclib Succinate | 16 | $222,675 |
| Exemestane | 94 | $13,906 |
| Anastrozole | 534 | $8,863 |
| EliquisApixaban | 13 | $7,381 |
| Letrozole | 49 | $1,026 |
| Raloxifene Hcl | 12 | $823 |
| Tamoxifen Citrate | 25 | $575 |
| Gabapentin | 31 | $376 |
| Omeprazole | 11 | $109 |
| Alendronate Sodium | 20 | $85 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in New Hyde Park
- Richard GrallaNew Hyde Park$159K
- Tarun WasilNew Hyde Park$147K
- Michael SchusterNew York$1.6M
- Charles SawyersNew York$1.6M
- Manuel Hidalgo-MedinaNew York$1.4M
- Francis ArenaLake Success$1M
- Sanjeev JainEast Patchogue$971K
- Ross LevineNew York$968K
- Perry CookBrooklyn$803K
- Mihir RavalAlbany$767K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.